35 studies found for:    Open Studies | "Carcinoid Tumor"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Carcinoid Tumor"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Conditions: Atypical Carcinoid Tumor;   Foregut Carcinoid Tumor;   Hindgut Carcinoid Tumor;   Lung Carcinoid Tumor;   Metastatic Carcinoid Tumor;   Metastatic Digestive System Neuroendocrine Tumor G1;   Midgut Carcinoid Tumor;   Recurrent Digestive System Neuroendocrine Tumor G1;   Recurrent Merkel Cell Carcinoma;   Regional Digestive System Neuroendocrine Tumor G1;   Stage IIIA Merkel Cell Carcinoma;   Stage IIIB Merkel Cell Carcinoma;   Stage IV Merkel Cell Carcinoma;   Thyroid Gland Medullary Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Pazopanib Hydrochloride;   Other: Placebo;   Other: Quality-of-Life Assessment
2 Recruiting A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors
Condition: Carcinoid Tumors
Interventions: Drug: Lanreotide;   Drug: Placebo (for sunitinib);   Drug: Sunitinib
3 Recruiting Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Conditions: Carcinoid Tumor;   Pancreatic Neuroendocrine Tumor
Intervention: Drug: Cabozantinib
4 Recruiting Natural History of Familial Carcinoid Tumor
Condition: Carcinoid
5 Recruiting Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Conditions: Carcinoid Tumors;   Pancreatic NET
Intervention: Drug: Ibrutinib
6 Recruiting A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours
Conditions: Carcinoid Tumor of the Small Bowel;   Neuroendocrine Tumour
Interventions: Drug: Octreotide LAR;   Drug: 177Lu-DOTA0-Tyr3-Octreotate
7 Recruiting Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
Conditions: Carcinoid Tumor;   Metastatic Carcinoid Tumor;   Neuroendocrine Neoplasm
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Nintedanib;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment
8 Unknown  Study Investigating MEN1 and SDHD in Familial Carcinoid Tumors
Condition: Carcinoid Neuroendocrine Cancer
9 Unknown  An Investigation of Small Intestinal Carcinoid Carcinoma in Families
Condition: Carcinoid Carcinoma
10 Recruiting YF476 in Patients With Type II Gastric Carcinoids Associated With Zollinger-Ellison Syndrome
Condition: Carcinoid
Intervention: Drug: YF476
11 Not yet recruiting Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Metastatic Gastrointestinal Carcinoid Tumor;   Pancreatic Polypeptide Tumor;   Pulmonary Carcinoid Tumor;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Somatostatinoma
Interventions: Drug: regorafenib;   Other: laboratory biomarker analysis
12 Unknown  Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors
Conditions: Brain and Central Nervous System Tumors;   Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Neuroblastoma;   Pheochromocytoma;   Sarcoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Radiation: yttrium Y 90-edotreotide
13 Not yet recruiting 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors
Conditions: Neuroendocrine;   Neuroendocrine Tumor;   Neuroendocrine Cancer;   Neuroendocrine Carcinoma;   Carcinoid;   Carcinoid Tumor;   Islet Cell Tumor;   Apudoma
Intervention: Drug: 68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.
14 Recruiting Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms
Condition: Carcinoid Syndrome
Intervention: Drug: Telotristat etiprate tablets (250 mg)
15 Available [18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA) Positron Emission Tomography (PET) in Neuroendocrine Tumours
Conditions: Thyroid Cancer, Medullary;   Carcinoid Tumor;   Pheochromocytoma;   Paraganglioma;   Insulinoma;   Neuroblastoma
Intervention: Drug: [18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA)
16 Recruiting SwissNET - a Registry for Neuroendocrine Tumours in Switzerland
Conditions: Neuroendocrine Tumors;   Carcinoid Tumor
17 Recruiting Theranostics: 68GaDOTATOC and 90YDOTATOC
Conditions: Neuroendocrine Tumors;   Carcinoid Tumors;   Neuroblastoma;   Medulloblastoma
Interventions: Drug: 90Y-DOTA-tyr3-Octreotide;   Radiation: Dosimetry-Guided Peptide Receptor Radiotherapy;   Drug: Aminosyn II
18 Not yet recruiting Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
Conditions: Neuroendocrine Tumors;   Carcinoid Tumors;   Neuroblastoma;   Medulloblastoma
Intervention: Drug: 68Ga-DOTATOC PET/CT
19 Recruiting 68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)
Conditions: Neuroendocrine Tumors;   Carcinoid Tumors
Intervention: Device: 68Ga-DOTATOC PET
20 Recruiting Evaluation of Gallium-68 DOTA-TOC Imaging of Somatostatin Receptor Positive Malignancies
Conditions: Neuroendocrine Tumor;   Paraganglioma;   Carcinoid Tumors;   Neuroblastoma
Intervention: Drug: DOTA-TOC PET/CT

   Previous Page Studies Shown (1-20) Next Page (21-35) Show next page of results    Last Page
Indicates status has not been verified in more than two years